Treatment of P. vivax Malaria in G6PD Deficiency
For acute P. vivax malaria in G6PD-deficient patients, treat the acute infection with chloroquine (or artemisinin-based combination therapy if chloroquine-resistant), then provide radical cure with weekly primaquine at 0.75 mg/kg (maximum 45 mg) for 8 weeks with close monitoring for hemolysis—but only in patients with intermediate G6PD deficiency (30-70% activity) and non-Mediterranean variants; avoid primaquine entirely in severe G6PD deficiency (<30% activity) or Mediterranean variants. 1
Acute Phase Treatment
First-line for blood-stage infection:
- Chloroquine: 1000 mg salt initially, then 500 mg at 6,24, and 48 hours 1
- Alternative if chloroquine-resistant (Papua New Guinea, Indonesia): Use artemisinin-based combinations (DHA-piperaquine or artemether-lumefantrine) 1
The acute treatment is the same regardless of G6PD status—G6PD deficiency does not affect these medications.
Radical Cure (Anti-Relapse Treatment)
This is where G6PD status becomes critical. The approach depends on the degree of G6PD deficiency and the variant type:
For Intermediate G6PD Deficiency (30-70% activity) with African A- variant:
- Weekly primaquine: 0.75 mg base/kg (maximum 45 mg) once weekly for 8 weeks 1
- Close monitoring for hemolysis is mandatory 1
- Research confirms this regimen causes less hemolysis than daily dosing, though still carries risk 2, 3
For Severe G6PD Deficiency (<30% activity) or Mediterranean B- variant:
- Do NOT use primaquine 1
- Mediterranean variants have "very high risk of severe haemolysis which may even be caused by extended dosing regimens" 1
- No safe primaquine regimen exists for this population
- Consider tafenoquine is also contraindicated (<70% activity threshold) 1
For G6PD Normal (≥70% activity):
- Standard primaquine: 30 mg base daily for 14 days 1
- Or tafenoquine: single 300 mg dose (if available and ≥70% activity) 1
Critical Clinical Considerations
G6PD Testing Timing: Recent evidence suggests G6PD activity may be falsely elevated during acute malaria due to reticulocytosis 4, 5. However, the 2024 guideline still recommends testing before treatment 1. If testing shows normal activity during acute infection but the patient is actually deficient, they face hemolysis risk with standard dosing.
Monitoring for Hemolysis:
- Symptoms typically appear on days 2-3 of primaquine treatment 6
- All severe cases present within 7 days of starting primaquine 6
- Clinical review within the first 5 days is critical 6
- Watch for: dark urine, pallor, fatigue, jaundice, tachycardia
- Monitor hemoglobin levels closely, especially days 3-7
Hemolysis Risk Data:
- With standard daily primaquine (0.5 mg/kg/day), approximately 1/3 of patients in high-prevalence areas experience clinically concerning hemoglobin declines 7
- Higher doses (1 mg/kg/day for 7 days) caused clinically significant hemolysis in 53% of G6PD heterozygous females versus 13% with standard 14-day dosing 3
- Blood transfusion required in 6.9% of severe hemolysis cases; mortality 6.9% 6
Common Pitfalls
Assuming phenotypically "normal" G6PD testing excludes all risk: Standard fluorescent spot tests miss heterozygous females with intermediate deficiency due to X-chromosome inactivation patterns 3. These patients can still experience severe hemolysis with higher primaquine doses.
Using daily primaquine dosing in populations with high G6PD deficiency prevalence without testing: This causes preventable severe hemolysis and transfusions 8, 7
Not distinguishing between G6PD variant types: Mediterranean variants are at much higher hemolysis risk than African variants, even with weekly dosing 1
Inadequate monitoring: Most severe hemolysis occurs in the first week—patients need close follow-up during this period, not just at day 14 6
Pregnancy and Breastfeeding
Do not use primaquine or tafenoquine in pregnant or breastfeeding women 1. Defer radical cure until after pregnancy/breastfeeding, using chloroquine prophylaxis if needed to suppress relapses.